Promising strategic partnership with Takeda

Published:
February 12, 2024
|
Last Updated:
January 27, 2026

We are thrilled to announce the strategic collaboration between Atinary and Takeda, the largest Japanese pharmaceutical company, to drive innovation in healthcare.

This partnership brings together our complementary expertise, paving the way for innovative AI solutions poised to transform pharmaceutical R&D and accelerate drug discovery. Through this collaboration, Takeda will leverage Atinary’s leading AI Self-Driving Labs technology, that combined with its expertise in R&D and drug discovery aim to create a more robust and efficient drug development process, ultimately benefiting patients worldwide.

At Atinary, we are committed to harnessing the power of AI, data science, robotics, and cloud computing to dramatically accelerate the discovery and development of breakthrough molecules. Our collaboration with Takeda Pharmaceuticals is a significant step towards achieving this goal.

We look forward to working together to revolutionize the field of drug development and improve healthcare outcomes.

In the news

Related Articles

  • Atinary Recognized in the Gartner® Hype Cycle™ for Life Science R&D, 2026 Report

    Atinary has been recognized as a Sample Vendor in the…

  • Atinary Named a World Economic Forum 2026 Technology Pioneer

    Atinary has been named a 2026 Technology Pioneer by the…

  • Podcast: Atinary and the Swiss BioTools Community

    Atinary Co-Founder & CTO Dr. Loïc Roch discusses Self-Driving Labs®…